DOCSLIB.ORG

Federal Research Programme on Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

FEDERAL RESEARCH PROGRAMME ON DRUGS NPS-care Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective Tina Van Havere (University of Applied Sciences and Art Ghent), Freya Vander Laenen (University of Ghent, IRCP), Charlotte Colman (University of Ghent, IRCP), Peter Blanckaert (Sciensano), Lies Gremeaux (Sciensano), Sarah Simonis (Sciensano), Anton Van Dijck (University of Applied Sciences and Art Ghent) Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective NPS-care Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective Contract - DR/02/79 FINAL REPORT PROMOTORS: dr. TINA VAN HAVERE (University of Applied Sciences and Art Ghent) Prof. Dr. FREYA VANDER LAENEN (University of Ghent, IRCP) Prof. Dr. CHARLOTTE COLMAN (University of Ghent, IRCP) Dr. LIES GREMAUX (Sciensano) Dr. PETER BLANKAERT (Sciensano) RESEARCHERS: SARAH SIMONIS (Sciensano) PRINCIPAL RESEARCHER: ANTON VAN DIJCK (University of Applied Sciences and Art Ghent) Federal Research Programme on Drugs 2 Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective Published in 2020 by the Belgian Science Policy Office (BELSPO) WTCIII Simon Bolivarlaan 30 Boulevard Simon Bolivar 30 B-1000 Brussels Belgium Tel: +32 (0)2 238 34 11 - Fax: +32 (0)2 230 59 12 http://www.belspo.be http://www.belspo.be/drugs Contact person: Aziz Naji Tel: +32 (0)2 238 35 72 Neither the Belgian Science Policy Office nor any person acting on behalf of the Belgian Science Policy Office is responsible for the use which might be made of the following information. The authors are responsible for the content. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without indicating the reference : Van Havere, T., Vander Laenen, F., Colman, C., Gremaux, L., Blankaert, P., Simonis, S., & Van Dijck, A. (2020). Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective. Final Report. Brussels : Belgian Science Policy Office 2020 – 162 p. (Federal Research Programme on Drugs) Federal Research Programme on Drugs 3 Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective ACKNOWLEDGMENTS AND LIST OF MEMBERS OF THE FOLLOW UP COMMITTEE Thanks to our partners MEMBERS OF THE FOLLOW UP COMMITTEE Martijn Onsia & Eric Genbrugge (Safe ‘n Sound), Lucia Casero (Eurotox), Katia Huard (FPS Public Health), Ferrara Maurizio (Info-drogues ASBL), Sarah Wille & Filip Van Durme (NICC), Paul Calle (Maria Middelares & UGent), Marc Vancoillie & Stephanie Ovaere (DJSOC/Federal Police), Roy Somers (AZ Herentals), Tessa Windelinckx (Free Clinic, coördinator Flemish Needle & Syringe Programs), Bérénice Libois & Matthieu Mean (Modus Vivendi), Jochen Schrooten (VAD), Claude Gillard (FGOV Justice), Sara Van Malderen (FOD Justice), David Fraters (CAD-Limburg). Federal Research Programme on Drugs 4 Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective Table of content TABLE OF CONTENT 5 CHAPTER 1: UNDERSTANDING NEW PSYCHOACTIVE SUBSTANCE USE IN BELGIUM FROM A HEALTH PERSPECTIVE 11 1. Introduction ............................................................................................................................................. 11 2. What are New Psychoactive Substances? ............................................................................................... 11 2.1. Definition of ‘New Psychoactive Substances’ (NPS) 11 2.2. The origins and evolution of NPS 13 2.2.1. A brief historical perspective on NPS 13 2.2.2. Characteristics of the NPS phenomenon. 14 2.2.3. ‘Legal highs’; the legislative factor 15 2.3. Terminology and concepts 15 2.3.1. Synthetic or natural? 15 2.3.2. ‘New’ or old? 16 2.3.3. ‘Cross-overs’: ketamine and Gamma-Hydroxybutyric Acid (GHB) 16 2.3.4. ‘Psychoactive Substances’ 17 2.4. New and newly used NPS 17 3. Classification of NPS ................................................................................................................................ 18 3.1. General taxonomy 18 3.2. Classes of NPS, forms and usage 19 3.2.1. Synthetic cannabinoids or Synthetic Cannabinoid Receptor Agonists (SCRA’s) 19 3.2.2. Stimulants 20 3.2.3. Empathogens 20 3.2.4. Synthetic Opioids (SO) 20 3.2.5. Depressants 20 3.2.6. Hallucinogens/psychedelics 21 3.2.7. Dissociatives 21 4. Legislation surrounding NPS .................................................................................................................... 21 4.1. The international dimension of NPS legislation 21 Federal Research Programme on Drugs 5 Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective 4.2. European legislation on NPS 21 4.3. National NPS laws: from observer to conductor 22 4.4. Belgium’s generic legislation targeting NPS 23 4.4.1. The national Drug Law of 1921 23 4.4.2. The generic Drug Law of 2017 24 4.5. Prohibition as a precaution 24 5. Current reports on NPS ........................................................................................................................... 25 5.1. Epidemiology of NPS use 25 5.1.1. Prevalence of NPS use around the world 25 5.1.2. Prevalence of NPS use in Europe 26 5.1.3. The use of NPS in Belgium 27 5.1.4. Other information sources 29 5.2. NPS as a (public) health issue 29 5.2.1. The ‘unknowns’ surrounding NPS 29 5.2.2. Substance (market) characteristics and health consequences 30 5.2.3. Health hazards, acute and chronic effects of NPS use 30 5.2.4. Challenges to the specialized health care field 31 6. The NPS-care project ............................................................................................................................... 31 6.1. General outline 32 6.2. The user’s perspective (Part I) 32 6.3. The professionals’ perspective (Part II) 32 6.4. Inventory of good practices in prevention, treatment and harm reduction for NPS users and feasibility study (Part III). 33 6.5. Research report 33 6.6. Ethical considerations 33 CHAPTER 2: THE USE OF NPS AND THE NEEDS REGARDING PREVENTION, TREATMENT AND HARM REDUCTION: THE USER’S PERSPECTIVE 42 1. Introduction ............................................................................................................................................. 42 2. Methods .................................................................................................................................................. 43 3. Results ..................................................................................................................................................... 44 Federal Research Programme on Drugs 6 Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective 3.1. Context and motivations of NPS use 46 3.1.1. Specific profile of NPS users 46 3.1.2. Motivations of NPS use 47 3.1.3. Connection between NPS, classic illicit substances and alcohol 52 3.1.4. Mode of use, evolution in use and consequences 53 3.2. Health needs 55 3.2.1. Users’ specific measures and harm reduction 55 3.2.2. The users’ perspective on (health) needs 57 3.2.3. Online market 59 3.2.4. Drug legislation and illegal status 60 3.3. Conclusion 61 CHAPTER 3: THE USE OF NPS AND THE AWARENESS OF USERS: THE SAMPLE COLLECTION 75 1. Introduction ............................................................................................................................................. 75 2. Methods .................................................................................................................................................. 75 3. Results ..................................................................................................................................................... 76 3.1. Pharmacological aspects 76 3.2. Social aspects 79 3.2.1. The terminology 79 3.2.2. Information 81 3.2.3. Source of acquisition 82 4. Conclusion ............................................................................................................................................... 82 CHAPTER 4 - TAILORED PREVENTION AND CARE FOR NPS USERS: THE PROFESSIONAL’S PERSPECTIVE 85 1. Introduction ............................................................................................................................................. 85 2. Methodology: two-step mixed method design ....................................................................................... 86 2.1. The Nominal Group Technique 86 2.1.1. Composition of the NGT’s 86 2.1.2. The NGT process 87 2.1.3. Analysis 88 2.2. The online survey 89 Federal Research Programme on Drugs 7 Project DR/02/79 - Understanding New Psychoactive Substance (NPS) use in Belgium from a health perspective 2.2.1. The survey as part of a mixed method design 89 2.2.2. Design of the NPS care survey 89 2.2.3. Central content of the NPS care survey 89 2.2.4. The inventory of needs presented in the NPS care survey 90 2.2.5. The collection of survey responses 91 3. Results NGT’s ........................................................................................................................................... 92 3.1. General information: location, timing and sampling 92 3.1.1. Dutch speaking NGT’s (NGT1 and 2) 92 3.1.2. French speaking NGT’s (NGT 3, 4 and 5) 92 3.2. Primary analysis: description
Recommended publications
  • SARS-Cov-2 Prevalence and Seroprevalence Among Healthcare Workers in Belgian Hospitals: Baseline Results of a Prospective Cohort Study

    SARS-Cov-2 Prevalence and Seroprevalence Among Healthcare Workers in Belgian Hospitals: Baseline Results of a Prospective Cohort Study

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.03.20204545; this version posted October 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: SARS-CoV-2 Prevalence and Seroprevalence among Healthcare Workers in Belgian Hospitals: Baseline Results of a Prospective Cohort Study Authors*: Laure Mortgat1,2, MD Cyril Barbezange3, PhD Natalie Fischer3,4, PhD Leo Heyndrickx5, MSc Veronik Hutse3, PhD Isabelle Thomas3, PhD Bea Vuylsteke6, PhD Kevin Arien5,7,8, PhD Isabelle Desombere3,8, PhD Els Duysburgh1,8, PhD Affiliations: 1. Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium 2. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 3. Department of Infectious diseases in humans, Sciensano, Brussels, Belgium 4. European Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 5. Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium 6. Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium 7. University of Antwerp 8. Equal contributions as last author *alphabetical order for middle authors Corresponding author: Laure Mortgat, Rue Juliette Wytsman 14, 1050 Brussels, BelgiumNOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. [email protected], + 32 2 642 57 42 medRxiv preprint doi: https://doi.org/10.1101/2020.10.03.20204545; this version posted October 6, 2020.
  • Moves to Amend HF No. 2711 As Follows

    Moves to Amend HF No. 2711 As Follows

    05/05/20 ​ REVISOR KLL/JK A20-0767​ 1.1 .................... moves to amend H.F. No. 2711 as follows:​ 1.2 Delete everything after the enacting clause and insert:​ 1.3 "ARTICLE 1​ 1.4 APPROPRIATIONS​ 1.5 Section 1. APPROPRIATIONS.​ 1.6 The sums shown in the column under "APPROPRIATIONS" are added to or reduce the​ 1.7 appropriations in Laws 2019, First Special Session chapter 5, to the agencies and for the​ 1.8 purposes specified in this article. The appropriations are from the general fund, or another​ 1.9 named fund, and are available for the fiscal year indicated for each purpose.​ 1.10 APPROPRIATIONS​ 1.11 Available for the Year​ 1.12 Ending June 30​ 1.13 2020​ 2021​ 1.14 Sec. 2. CORRECTIONS​ 1.15 Subdivision 1. Total Appropriation​ $​ 205,000​ $​ 5,545,000​ 1.16 The amounts that may be spent for each​ 1.17 purpose are specified in the following​ 1.18 subdivisions.​ 1.19 Subd. 2. Correctional Institutions​ -0-​ (2,545,000)​ 1.20 To account for overall bed impact savings of​ 1.21 reductions in the penalties for controlled​ 1.22 substances offenses involving the possession​ 1.23 of marijuana, investments in community​ 1.24 supervision, and increased penalties for sex​ 1.25 trafficking offenses, the fiscal year 2021​ Article 1 Sec. 2.​ 1​ 05/05/20 ​ REVISOR KLL/JK A20-0767​ 2.1 appropriation from Laws 2019, First Special​ 2.2 Session chapter 5, article 1, section 15,​ 2.3 subdivision 2, is reduced by $2,545,000.​ 2.4 Subd.
  • Covid-19 Surveillance in Residential Institutions

    Covid-19 Surveillance in Residential Institutions

    HEALTHCARE-ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE COVID-19 SURVEILLANCE IN RESIDENTIAL INSTITUTIONS Version 4.2 – 11/01/2021 _ S. DEQUEKER • K. LATOUR • E. ISLAMAJ • L. INT PANIS • M. CALLIES • L. CATTEAU • B. CATRY • E. VANDAEL W HO WE ARE _ SCIENSANO can count on more than 700 staff members who commit themselves, day after day, to achieving our motto: Healthy all lifelong. As our name suggests, science and health are central to our mission. Sciensano’s strength and uniqueness lie within the holistic and multidisciplinary approach to health. More particularly we focus on the close and indissoluble interconnection between human and animal health and their environment (the “One health” concept). By combining different research perspectives within this framework, Sciensano contributes in a unique way to everybody’s health. For this, Sciensano builds on the more than 100 years of scientific expertise of the former Veterinary and Agrochemical Research Centre (CODA-CERVA) and the ex-Scientific Institute of Public Health (WIV-ISP). 2 Sciensano Epidemiology and public health - Healthcare-associated infections and antimicrobial resistance Long-term care facilities December 2020 • Brussels • Belgium _ S. Dequeker1 • K. Latour1 • E. Islamaj1 • L. Int Panis1 • M. Callies1 • L. Catteau1 • B. Catry1 • E. Vandael1 1 Sciensano, Epidemiology and public health, Healthcare-associated infections and antimicrobial resistance, Brussels Contactperson: S. Dequeker • T+32 2 642 52 34 • [email protected] Please cite as: S. Dequeker, K. Latour, E. Islamaj, L. Int Panis, M. Callies, L. Catteau, B. Catry, E. Vandael. COVID-19 surveillance in residential institutions. Brussels, Belgium : Sciensano ; 2020 24p. TABLE OF CONTENTS TABLE OF CONTENTS ........................................................................................................................................
  • Belgium-Luxembourg-7-Preview.Pdf

    Belgium-Luxembourg-7-Preview.Pdf

    ©Lonely Planet Publications Pty Ltd Belgium & Luxembourg Bruges, Ghent & Antwerp & Northwest Belgium Northeast Belgium p83 p142 #_ Brussels p34 Wallonia p183 Luxembourg p243 #_ Mark Elliott, Catherine Le Nevez, Helena Smith, Regis St Louis, Benedict Walker PLAN YOUR TRIP ON THE ROAD Welcome to BRUSSELS . 34 ANTWERP Belgium & Luxembourg . 4 Sights . 38 & NORTHEAST Belgium & Luxembourg Tours . .. 60 BELGIUM . 142 Map . 6 Sleeping . 62 Antwerp (Antwerpen) . 144 Belgium & Luxembourg’s Eating . 65 Top 15 . 8 Around Antwerp . 164 Drinking & Nightlife . 71 Westmalle . 164 Need to Know . 16 Entertainment . 76 Turnhout . 165 First Time Shopping . 78 Lier . 167 Belgium & Luxembourg . .. 18 Information . 80 Mechelen . 168 If You Like . 20 Getting There & Away . 81 Leuven . 174 Getting Around . 81 Month by Month . 22 Hageland . 179 Itineraries . 26 Diest . 179 BRUGES, GHENT Hasselt . 179 Travel with Children . 29 & NORTHWEST Haspengouw . 180 Regions at a Glance . .. 31 BELGIUM . 83 Tienen . 180 Bruges . 85 Zoutleeuw . 180 Damme . 103 ALEKSEI VELIZHANIN / SHUTTERSTOCK © SHUTTERSTOCK / VELIZHANIN ALEKSEI Sint-Truiden . 180 Belgian Coast . 103 Tongeren . 181 Knokke-Heist . 103 De Haan . 105 Bredene . 106 WALLONIA . 183 Zeebrugge & Western Wallonia . 186 Lissewege . 106 Tournai . 186 Ostend (Oostende) . 106 Pipaix . 190 Nieuwpoort . 111 Aubechies . 190 Oostduinkerke . 111 Ath . 190 De Panne . 112 Lessines . 191 GALERIES ST-HUBERT, Beer Country . 113 Enghien . 191 BRUSSELS P38 Veurne . 113 Mons . 191 Diksmuide . 114 Binche . 195 MISTERVLAD / HUTTERSTOCK © HUTTERSTOCK / MISTERVLAD Poperinge . 114 Nivelles . 196 Ypres (Ieper) . 116 Waterloo Ypres Salient . 120 Battlefield . 197 Kortrijk . 123 Louvain-la-Neuve . 199 Oudenaarde . 125 Charleroi . 199 Geraardsbergen . 127 Thuin . 201 Ghent . 128 Aulne . 201 BRABO FOUNTAIN, ANTWERP P145 Contents UNDERSTAND Belgium & Luxembourg Today .
  • Semaine / Week 11 (09/02/2020 – 15/03/2020)

    Semaine / Week 11 (09/02/2020 – 15/03/2020)

    INFECTIOUS DISEASES IN HUMANS - VIRAL DISEASES – NRC INFLUENZA EPIDEMIOLOGY AND PUBLIC HEALTH - EPIDEMIOLOGY OF INFECTIOUS DISEASES W EKELIJKS I NFLUENZA BULLETIN B ULLETIN HEBDOMADAIRE I NFLUENZA W EEKLY I NFLUENZA BULLETIN Semaine / week 11 (09/02/2020 – 15/03/2020) 1 Sciensano Epidemiology and public health - Epidemiology of infectious diseases Infectious diseases in humans - Viral diseases – NRC Influenza Met de financiële steun van Contact Persons: Epidemiological data: Nathalie Bossuyt • [email protected] Dieter Van Cauteren • [email protected] Natalia Bustos Sierra • [email protected] (Mortality) Virological data: Isabelle Thomas • [email protected] Cyril Barbezange • [email protected] Report number: ISSN 2593-4309 Available on: https://epidemio.wiv-isp.be/ID/diseases/Pages/Influenza.aspx 2 OVERZICHT WEEK 11 R ÉSUMÉ SEMAINE 11 OVERVIEW WEEK 11 In de afgelopen week steeg de to- La semaine passée, l’incidence de Last week, the incidence of visits to tale incidentie van raadplegingen consultations chez le médecin géné- the general practitioner for influ- voor griepaal syndroom tot 448 raliste pour syndrome grippal a aug- enza like illness increased to 448 raadplegingen per 100.000 inwo- menté jusqu’à 448 consultations consultations per 100,000 inhabit- ners (inclusief telefonische raadple- pour 100.000 habitants (consulta- ants (including contact by phone). gingen). De incidentie stijgt in alle tions téléphoniques inclus). L’inci- The incidence increases in all age leeftijdsgroepen in Wallonië en dence augmente dans chaque groups in the Walloon and Brussels Brussel en bij kinderen in Vlaande- tranche d’âge en Wallonie et chez Region and among children in the ren.
  • The Expression of Hemagglutinin by a Recombinant Newcastle Disease Virus Causes Structural Changes and Alters Innate Immune Sensing

    The Expression of Hemagglutinin by a Recombinant Newcastle Disease Virus Causes Structural Changes and Alters Innate Immune Sensing

    Article The Expression of Hemagglutinin by a Recombinant Newcastle Disease Virus Causes Structural Changes and Alters Innate Immune Sensing Fiona Ingrao 1,* , Victoria Duchatel 1, Isabel Fernandez Rodil 2, Mieke Steensels 1, Eveline Verleysen 3, Jan Mast 3 and Bénédicte Lambrecht 1 1 Service of Avian Virology and Immunology, Sciensano, 1180 Brussels, Belgium; [email protected] (V.D.); [email protected] (M.S.); [email protected] (B.L.) 2 Institut de Biologie et Médecine Moléculaire, Université Libre de Bruxelles, 6041 Gosselies, Belgium; [email protected] 3 Service of Trace Elements and Nanomaterials, Sciensano, 1180 Brussels, Belgium; [email protected] (E.V.); [email protected] (J.M.) * Correspondence: fi[email protected] Abstract: Recombinant Newcastle disease viruses (rNDV) have been used as bivalent vectors for vaccination against multiple economically important avian pathogens. NDV-vectored vaccines ex- pressing the immunogenic H5 hemagglutinin (rNDV-H5) are considered attractive candidates to protect poultry from both highly pathogenic avian influenza (HPAI) and Newcastle disease (ND). However, the impact of the insertion of a recombinant protein, such as H5, on the biological charac- teristics of the parental NDV strain has been little investigated to date. The present study compared Citation: Ingrao, F.; Duchatel, V.; a rNDV-H5 vaccine and its parental NDV LaSota strain in terms of their structural and functional Rodil, I.F.; Steensels, M.; Verleysen, E.; characteristics, as well as their recognition by the innate immune sensors. Structural analysis of the Mast, J.; Lambrecht, B. The rNDV-H5 demonstrated a decreased number of fusion (F) and a higher number of hemagglutinin- Expression of Hemagglutinin by a Recombinant Newcastle Disease neuraminidase (HN) glycoproteins compared to NDV LaSota.
  • Page 1 1 HEALTHCARE-ASSOCIATED

    Page 1 1 HEALTHCARE-ASSOCIATED

    HEALTHCARE-ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE S URVEILLANCE OF ANTIMICROBIAL RESISTA NT BACTERIA IN B ELGIAN HOSPITALS Report 2018 – 1 EXECUTIVE SUMMARY W HO WE ARE – SCIENSANO can count on more than 700 staff members who commit themselves, day after day, to achieving our motto: Healthy all life long. As our name suggests, science and health are central to our mission. Sciensano’s strength and uniqueness lie within the holistic and multidisciplinary approach to health. More particularly we focus on the close and indissoluble interconnection between human and animal health and their environment (the “One health” concept). By combining different research perspectives within this framework, Sciensano contributes in a unique way to everybody’s health. For this, Sciensano builds on the more than 100 years of scientific expertise of the former Veterinary and Agrochemical Research Centre (CODA-CERVA) and the ex-Scientific Institute of Public Health (WIV-ISP). 2 Sciensano Epidemiology and public health – Healthcare-associated infections and antimicrobial resistance January 2020 • Brussels • Belgium Internal reference number: D/2020/14.440/8 ISSN: 2593-7073 – Latour K.1 In collaboration with Prof. Dr. Herman Goossens2, Dr. Marie Hallin3, Prof. Dr. Te-Din Huang4 1 Sciensano, Epidemiology and public health, Healthcare-associated infections and antimicrobial resistance, Brussels 2 National reference centre for resistant enterococci, Universiteit Antwerpen, UZ Antwerpen, Antwerpen 3. National reference centre for Staphylococcus aureus, Université Libre de Bruxelles, Hôpital Erasme, Brussels 4. National reference centre for resistant Gram-negative bacilli, Université Catholique de Louvain, CHU UCL Namur (Godinne), Yvoir Katrien Latour • T+32 2 642 57 62 • [email protected] Partners The surveillances of antimicrobial resistant bacteria are organised with the support of the Belgian Antibiotic Policy Coordination Committee (BAPCOC) and are financially supported by the Federal Public Service Public Health, Food Chain Safety and Environment.
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)

    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)

    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
  • Appendix-2Final.Pdf 663.7 KB

    Appendix-2Final.Pdf 663.7 KB

    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
  • Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J

    Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Hertfordshire Research Archive Citation for the published version: Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J. M., ... vento, A. (2019). New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues. Current Addiction Reports, 6(2), 140-152. https://doi.org/10.1007/s40429-019-00249-z Document Version: Accepted Version The final publication is available at Springer Nature via https://doi.org/10.1007/s40429-019-00249-z © 2019 Springer Nature Publishing AG General rights Copyright© and Moral Rights for the publications made accessible on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (http://uhra.herts.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge. Take down policy If you believe that this document breaches copyright please contact us providing details, any such items will be temporarily removed from the repository pending investigation.
  • Alcohol and Drug Abuse Subchapter 9

    Alcohol and Drug Abuse Subchapter 9

    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
  • G.S. 90-89 Page 1 § 90-89. Schedule I Controlled Substances. This

    G.S. 90-89 Page 1 § 90-89. Schedule I Controlled Substances. This

    § 90-89. Schedule I controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse, no currently accepted medical use in the United States, or a lack of accepted safety for use in treatment under medical supervision. The following controlled substances are included in this schedule: (1) Opiates. – Any of the following opiates or opioids, including the isomers, esters, ethers, salts and salts of isomers, esters, and ethers, unless specifically excepted, or listed in another schedule, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetyl-alpha-methylfentanyl (N[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacet amide). b. Acetylmethadol. c. Repealed by Session Laws 1987, c. 412, s. 2. d. Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl/-4-piperidinyl]-N-phenylpro panamide). e. Allylprodine. f. Alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate and LAAM). g. Alphameprodine. h. Alphamethadol. i. Alpha-methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionalilide; 1(1-methyl-2-phenyl-ethyl)-4-(N-propanilido) piperidine). j. Benzethidine. k. Betacetylmethadol. l. Beta-hydroxfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide ). m. Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpro panamide). n. Betameprodine. o. Betamethadol. p. Betaprodine. q. Clonitazene. r. Dextromoramide. s. Diampromide. t. Diethylthiambutene. u.